MabCampath
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Section I: Technologies Foreword A Greeting from the Editor PART 0: INTRODUCTION Therapeutic Antibodies - From Past to Future…
Fludarabine-refractory CLL has a poor prognosis with a median overall survival time of less than 12 months despite salvage…
CAM307 is a phase III, open-label, multinational, randomized controlled trial comparing alemtuzumab (CAM) with chlorambucil (CHLO…
Megakaryocyte colony-forming unit growth is enhanced by alemtuzumab: in vitro experiments and a case report of acquired…
CAM307 is a randomized Phase III trial comparing the efficacy and safety of alemtuzumab (CAM) with chlorambucil (CHLO). The trial…
Abstract Alemtuzumab (Campath 1H -MabCampath), initially used for prophylaxis of graft versus host disease in allogenic…
Alemtuzumab reduces the incidence of acute and chronic GvHD following stem cell transplantation and reduces GvHD-related…
CAMPATH® (CAMPATH-1H, alemtuzumab, MabCAMPATH), is a lymphocyte-depleting humanized monoclonal antibody that was recently…